MEMPHIS, TN, United States

Molecular Design International, Inc.

www.moleculardesign.com
MEMPHIS, TN, United States
SEARCH FILTERS
Time filter
Source Type

Grant
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase I | Award Amount: 108.40K | Year: 2011

DESCRIPTION (provided by applicant): The overall goal of our work is to establish the potency and efficacy of a novel 2-adrenergic receptor agonist (compound 49b) in the prevention and/or reversal of non-proliferative diabetic retinopathy. Diabetic retinopathy is the leading cause of blindness in working age adults. The current treatment paradigm for retinopathy patients has not changed significantly since laser photocoagulation became popular in the 1970's. Work needs to be completed to develop a noveltreatment for diabetic retinopathy that prevents the progression of the disease from the non-proliferative form to the proliferative form. We have data demonstrating that elimination of sympathetic neurotransmission to the rat retina reproduces the biochemical and histological features of non-proliferative diabetic retinopathy, which were reproduced when rats were treated with a beta-adrenergic receptor antagonist. We have now demonstrated both in vitro and in vivo that maintenance of beta- adrenergic receptor signaling in the diabetic rat retina can inhibit the loss of retinal function and morphology. This maintenance of visual function was associated with a decreased level of inflammatory cytokines and increased insulin receptor signaling. Unfortunately,topical isoproterenol has a narrow dose range and is not a commercially viable product. The projects in this proposal will test a novel beta-adrenergic receptor agonist for topical application to prevent/reverse experimental non-proliferative retinopathy.In this phase 1 STTR, we will demonstrate acute efficacy, pharmacokinetics, and potency of compound 49b in cell culture and in diabetic rats. Translation of this work into patient care will be expedited, as functional studies on the diabetic rodents will mirror those studies that occur in human subjects. The use of chemically novel compounds will allow for increased interest from both industry and federal funding. The deliverables from this project are pre-IND enabling data that will facilitate movement ofCompound 49b into FDA approval and human clinical trials. PUBLIC HEALTH RELEVANCE: The work proposed in this study will test a novel therapeutic agent to prevent/treat diabetic retinopathy using topical application. The proposed studies will demonstrate efficacy, safety and potency of compounds 49b to inhibit diabetic retinopathy


PubMed | Molecular Design International, Inc.
Type: Journal Article | Journal: Proceedings of the National Academy of Sciences of the United States of America | Year: 2010

Empirical force-field calculations show that bis(9-triptycyl)methane has a C(s) ground state and that the securely meshed triptycyl groups undergo nearly unhindered cogwheel rotation through a C(2) transition state, with an activation energy of approximately 1.0 kcal mol(-1). These features lead to note-worthy stereochemical attributes in appropriately substituted derivatives and analogs. Bis(9-triptycyl)carbinol has been prepared as an example of a compound that is chemically achiral, even though all conformations are chiral under the constraint of gear meshing. It is shown that, under the same constraint, ring substitution of either compound (or analogous systems) may lead to residual stereoisomerism. A permutational analysis of chemical isomers and isomerizations for every possible type of substitution pattern gives an enumeration of residual stereoisomers under the operation of various gearing and nongearing modes and provides information essential for a choice among mechanistic alternatives for a given isomer count.


Trademark
Molecular Design International, Inc. | Date: 2014-05-29

Anti-aging cream containing a retinoic ingredient not for medical purposes; Cosmetic creams for skin care; Cosmetic preparations for skin care; Cosmetic preparations for skin renewal; Cosmetic skin fresheners; Moisturizing preparations for the skin; Moisturizing solutions for the skin; Non-foaming cosmetic preparations for skin care; Non-medicated cleansers for personal use, namely, skin; Non-medicated preparations all for the care of skin, hair and scalp; Non-medicated serums for use on skin; Non-medicated skin care preparations, namely, creams, lotions, gels, toners, cleaners and peels; Non-medicated skin creams; Non-medicated skin toners; Skin care preparations, namely, skin peels; Skin care products, namely, non-medicated skin serum; Skin cleansing cream; Skin cleansing lotion; Skin conditioners; Skin conditioning creams for cosmetic purposes; Skin cream; Skin creams; Skin creams in liquid and in solid form; Skin creams in liquid and solid; Skin creams in liquid and solid form; Skin emollients; Skin fresheners; Skin lotion; Skin lotions; Skin masks; Skin moisturizer; Skin moisturizing gel; Skin soap; Skin toners; Skin whitening creams; Skin whitening preparations; Wrinkle removing skin care preparations.


Molecular Design International, Inc. | Entity website

Molecular Design International, Inc. improving the world, one molecule at a time


Molecular Design International, Inc. | Entity website

Science & Skin By combining science and skin care and utilizing one of the leading formulators of dermatological products we have created the safest and most effective and best Anti-Aging product today. We made sure our second generation retinoid, RETEXTRA, was the active ingredient in the serum, and the result is our revolutionary Uth Radiance Serum ...


Molecular Design International, Inc. | Entity website

UT Researchers Target DiabetesCompound has potential to be "billion-dollar drug"2011 The Memphis Business JournalBy Michael Sheffield A new compound being developed at theUniversity of Tennessee Health ScienceCentercould be the link to preventing blindness in diabetic retinothropy patients. Ithas already received $1 million in research grants from theJuvenile DiabetesResearch Foundationand theNational Institutes of Health ...


Molecular Design International, Inc. | Entity website

William P. Purcell, Ph ...


Molecular Design International, Inc. | Entity website

MDI 301Wound Healing Drug MDI has a proprietary drug compound, MDI 301, that works effectively and safely for skin repair and wound healing. Documentation, data, and patent positions are available on request


Molecular Design International, Inc. | Entity website

Molecular Design International, Inc. improving the world, one molecule at a time


Molecular Design International, Inc. | Entity website

Discovery:MDI discovers, patents, and evaluates new drug candidates.MDI out licenses its proprietary drugs to pharmaceutical companies having the resources to develop them through the regulatory process and to market them aggressively ...

Loading Molecular Design International, Inc. collaborators
Loading Molecular Design International, Inc. collaborators